2016 Annual Meeting | Interventional Treatment of Migraine and Other Headache Disorders
06:30 AM - 06:40 AM |
Introduction
Morris Levin, MD, FAAN |
|
06:40 AM - 07:00 AM |
Nerve Blocks and Trigger Point Injections: Pharmacology and Technique
Morris Levin, MD, FAAN |
|
07:00 AM - 07:20 AM |
Evidence for Nerve Blocks and Trigger Point Injections in Headache
Thomas N. Ward, MD, FAAN |
|
07:20 AM - 07:50 AM |
Neurostimulation in Primary Headache Disorders – Options and Evidence
Morris Levin, MD, FAAN |
|
07:50 AM - 08:15 AM |
Inpatient Treatment of Headache – Options and Outcomes
Thomas N. Ward, MD, FAAN |
|
08:15 AM - 08:30 AM |
Questions and Answers
|
Morris Levin, MD, FAAN | Dr. Levin has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Supernus, Upsher Smith, Biohaven, Revance, Percept, Theranica, Allergan, Alder, Currax. Dr. Levin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theranica. Dr. Levin has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for Headache Cooperative of the Pacific. Dr. Levin has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Attorney . Dr. Levin has received stock or an ownership interest from Percept. Dr. Levin has received publishing royalties from a publication relating to health care. |
Thomas N. Ward, MD, FAAN | No disclosure on file |